Advanced Search

Study Preview



Study Title and Description

Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60.



Key Questions Addressed
3 Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60.
Author Cohen FJ., Watts S., Shah A., Akers R., Plouffe L.
Country Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
Year 2000
Numbers Pubmed ID: 10636511

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-4


Results & Comparisons

No Results found.